<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Congenital familial non-haemolytic <z:e sem="disease" ids="C0020433" disease_type="Disease or Syndrome" abbrv="">hyperbilirubinaemias</z:e> are potentially lethal syndromes caused by genetic lesions that reduce or abolish hepatic <z:chebi fb="0" ids="16990">bilirubin</z:chebi> <z:chebi fb="15" ids="17659">UDP</z:chebi>-glucuronosyltransferase activity </plain></SENT>
<SENT sid="1" pm="."><plain>Here we describe genetic defects that occur in the UGT1 gene complex that cause three non-haemolytic <z:e sem="disease" ids="C0268306" disease_type="Disease or Syndrome" abbrv="">unconjugated hyperbilirubinaemia</z:e> syndromes </plain></SENT>
<SENT sid="2" pm="."><plain>The most severe syndrome, termed <z:e sem="disease" ids="C0010324" disease_type="Disease or Syndrome" abbrv="">Crigler-Najjar syndrome</z:e> type I, is mainly associated with mutations in exons 2 to 5 that affect <z:hpo ids='HP_0000001'>all</z:hpo> UGT1 enzymes and many of the mutations result in termination codons and frameshifts </plain></SENT>
<SENT sid="3" pm="."><plain>Crigler-Najjar type II syndrome which is treatable with <z:chebi fb="1" ids="8069">phenobarbital</z:chebi> therapy is associated with less dramatic missense mutations or heterozygous expression of mutant and <z:mpath ids='MPATH_458'>normal</z:mpath> alleles </plain></SENT>
<SENT sid="4" pm="."><plain><z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e>, the most prevalent (2-19% in population studies) and mildest of the three syndromes is principally caused by a TA insertion at the TATA promoter region upstream of the UGT1A1 exon </plain></SENT>
<SENT sid="5" pm="."><plain>Current methods used for the diagnosis and treatment of these diseases are discussed </plain></SENT>
</text></document>